

## I. AMENDMENTS

### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

Claims 1. to 19. (Canceled).

20. (Previously Presented) A method for screening for therapeutic agents for administration in combination with (E)-5-(2-bromovinyl)-2'-deoxy-5'-uridyl phenyl L-alaninylphosphoramidate or (E)-5-(2-bromovinyl)-2'-deoxy-5'-uridyl phenyl L-alaninyl monophosphate, comprising contacting the candidate therapeutic agent and (E)-5-(2-bromovinyl)-2'-deoxy-5'-uridyl phenyl L-alaninylphosphoramidate or (E)-5-(2-bromovinyl)-2'-deoxy-5'-uridyl phenyl monophosphate with a cancer cell selected from the group consisting of a breast cancer cell, a non-small cell lung cancer cell, a rectal cancer cell, a head and neck cancer cell, a stomach cancer cell, a pancreatic cancer cell, a colon cancer cell, a liver cancer cell, a gastric cancer cell, a skin cancer cell, a bone cancer cell, a bone marrow cancer cell, a testicular cancer cell, a brain cancer cell, a lung cancer cell, a prostate cancer cell and an ovarian cancer cell, and wherein said cell endogenously overexpresses, intracellular thymidylate synthase enzyme and assaying for cell death.

21. (Previously Presented) The method of claim 20, further comprising contacting a normal cell with the candidate therapeutic agent and (E)-5-(2-bromovinyl)-2'-deoxy-5'-uridyl phenyl L-alaninylphosphoramidate or (E)-5-(2-bromovinyl)-2'-deoxy-5'-uridyl phenyl monophosphate and assaying for cell death.

Claims 22. to 33. (Canceled).

34. The method of claim 20, wherein the candidate therapeutic agent is contacted with the cell subsequent to contacting the cell with (E)-5-(2-bromovinyl)-2'-

deoxy-5'-uridyl phenyl L-alaninylphosphoramidate.

35. (Previously Presented) The method of claim 20, wherein the cell is resistant to (E)-5-(2-bromovinyl)-2'-deoxy-5'-uridyl phenyl L-alaninylphosphoramidate.

Claims 36. to 37. (Canceled).